The pen comes with half unit dosing increment and has been developed for children and teenagers between six and 18 years of age who are suffering from Type-1 diabetes. The pen can work with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin) and can deliver between 1 to 30 units per injection and has a single-step dial back.
"Everyone deserves high-quality care while learning to manage their diabetes, for the best chances in life. With JuniorSTAR, we aim to meet the needs of type 1 patients worldwide, specifically the younger ones, who need an easy-to-use pen device." This is a welcome addition to our comprehensive portfolio of established insulins, which leads the way in personalized diabetes care', the Senior Vice President, Global Diabetes, Sanofi, Pierre Chancel said.